Sclerosis multiplex (SM): vizsgálatok itt: Portugália
17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Lisbon, Porto, Santa Maria Da Feira, Senhora Da Hora
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 2. fázisTaking peopleA Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
- Where
- Braga, Coimbra
- Életkor
- 10 év to 17 év
- People
- 12 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07161258 · EU 2024-519800-28-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Lisbon, Porto, Santa Maria Da Feira, Senhora Da Hora
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - 3. fázisTaking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Braga, Guimarães, Matosinhos
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - 3. fázisTaking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Braga, Coimbra, Lisbon
- Életkor
- 40 év to 70 év
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Braga, Lisbon, Porto
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Braga, Coimbra, Guimaraes, Lisbon, Matosinhos
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - 2. fázisTaking peopleA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- Where
- Braga, Coimbra, Lisbon, Santa Maria Da Feira
- Életkor
- 18 év to 60 év
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00 - 3. fázisTaking peopleEfficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Where
- Coimbra, Lisbon
- Életkor
- Up to 17 év
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00 - 3. fázisTaking peopleStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Where
- Braga, Coimbra, Lisbon, Porto
- Életkor
- 10 év to 17 év
- People
- 194 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06408259 · EU 2022-501332-42-00 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Braga, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00 - No phaseNot yet taking people in PortugáliaSociocognitive Intervention and Rehabilitation Program in Multiple Sclerosis
- Where
- Coimbra
- Életkor
- 18 év to 55 év
- People
- 130
- Run by
- Sonia Batista
See details and how to joinNCT07734675 - No phaseTaking peopleOfatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
- Where
- Amadora, Guimarães, Leiria, Lisbon, Matosinhos Municipality, Ponte de Lima, Porto, Setúbal
- Életkor
- 18 év to 99 év
- People
- 174
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05809986 - 2. fázisTaking peoplePsilocybin Therapy for Psychological Distress in Palliative Patients
- Where
- Lisbon
- Életkor
- 18 év and over
- People
- 108 worldwide
- Run by
- University Medical Center Groningen
See details and how to joinNCT06782724 · EU 2023-510488-36-01 - 2. fázisTaking peopleA phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-Δ tetrahydrocannabinol/cannabidiol (THC/CBD) in multiple sclerosis patients with chronic neuropathic pain
- Where
- Braga
- Életkor
- 18 év and over
- People
- 68
- Run by
- Ferraz Lynce Especialidades Farmaceuticas S.A.
See details and how to join2024-520287-34-01 · EU 2024-520287-34-01 - 2. fázisTaking peopleMODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis
- Where
- Braga
- Életkor
- 18 év to 64 év
- People
- 64
- Run by
- Clinical Academic Center (2CA-Braga)
See details and how to joinNCT06592352 · EU 2022-501414-53-00 - No phaseTaking peopleImproving Learning and Memory in Portuguese Patients With Multiple Sclerosis
- Where
- Porto
- Életkor
- 18 év to 70 év
- People
- 80
- Run by
- Centro Hospitalar De São João, E.P.E.
See details and how to joinNCT06723444